DAEJEON, South Korea--(BUSINESS WIRE)--LegoChem Biosciences, Inc. (KOSDAQ: 141080) announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate (ADC)..

韩国大田--（商业新闻短讯）--LegoChem Biosciences，Inc.（KOSDAQ:141080）于12月22日宣布，已与强生公司Janssen Biotech，Inc.（Janssen）签订许可协议，开发和商业化LCB84，一种Trop2定向抗体药物偶联物（ADC）。。

Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84. LCB is eligible for up to potentially USD 1.7 billion in total consideration including an upfront payment of USD 100 million, an option exercise payment of USD 200 million as well as potential development, regulatory, and commercial milestone payments, plus tiered royalties on net sales.

根据协议条款，LCB将向杨森授予LCB84开发和商业化的全球独家许可证。LCB有资格获得高达17亿美元的总对价，包括1亿美元的预付款、2亿美元的期权行权款以及潜在的开发、监管和商业里程碑付款，以及净销售额的分层版税。

The companies will collaborate during the ongoing Phase 1/2 clinical trial, with Janssen solely responsible for clinical development and commercialization after option exercise..

这些公司将在正在进行的1/2期临床试验期间进行合作，杨森将全权负责期权行使后的临床开发和商业化。。

LCB84, a Trop2 directed ADC applying LCB’s next-generation ADC platform technology and Trop2 antibody licensed from Mediterranea Theranostic, S.r.l, is being studied in a recently initiated Phase 1/2 clinical trial in the U.S. The ADC has a distinctive targeted mechanism, binding a unique cleaved form of the Trop2 antigen, which is highly expressed in cancer cells.

LCB84是一种应用LCB下一代ADC平台技术和Mediterranea Theranostic s.r.l许可的Trop2抗体的Trop2定向ADC，正在美国最近启动的1/2期临床试验中进行研究。ADC具有独特的靶向机制，结合Trop2抗原的独特裂解形式，该抗原在癌细胞中高度表达。

Preclinical data demonstrated a differentiated safety and efficacy profile compared across multiple cancers, showing LCB84’s promise as a Trop2-targeting ADC..

临床前数据显示，与多种癌症相比，LCB84具有不同的安全性和有效性，显示LCB84有望成为靶向Trop2的ADC。。

“We are very pleased to collaborate with Janssen on LCB84, our first wholly in-house developed clinical stage ADC,” said Yong-Zu Kim, President and CEO of LCB. “We look forward to continuing to build our global clinical development capabilities and advance other ADC programs into the clinic.”

LCB总裁兼首席执行官金永祖（Yong Zu Kim）表示：“我们非常高兴与杨森（Janssen）就LCB84进行合作，LCB84是我们第一个完全由内部开发的临床阶段ADC。”。“我们期待着继续建立我们的全球临床开发能力，并将其他ADC项目推进临床。”

About LegoChem Biosciences, Inc.

关于LegoChem Biosciences，Inc。

LegoChem Biosciences, Inc. (KOSDAQ: 141080), is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on researching and developing Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics, and anti-fibrotic based on proprietary platform technologies.

LegoChem Biosciences，Inc.（KOSDAQ:141080）是一家临床阶段的生物制药公司，致力于利用其专有的药物发现技术Legochemical和ADC平台技术ConjuAll发现和开发下一代新型疗法。自2006年成立以来，LCB一直致力于基于专有平台技术研究和开发抗体-药物偶联物（ADC），抗癌疗法，抗生素和抗纤维化药物。

For more information, visit LegoChem Biosciences, Inc. at https://www.legochembio.com/index.php?lang=e..

欲了解更多信息，请访问LegoChem Biosciences，股份有限公司https://www.legochembio.com/index.php?lang=e..